Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration

Cell

Volumn 145, Issue 6, 2011, Pages 863-874

  Zwilling, Daniel ^a   Huang, Shao Yi ^a,c   Sathyasaikumar, Korrapati V ^d   Notarangelo, Francesca M ^d   Guidetti, Paolo ^d   Wu, Hui Qiu ^d   Lee, Jason ^a   Truong, Jennifer ^a   Andrews Zwilling, Yaisa ^a   Hsieh, Eric W ^a   Louie, Jamie Y ^a   Wu, Tiffany ^a   Scearce Levie, Kimberly ^a   Patrick, Christina ^e   Adame, Anthony ^e   Giorgini, Flaviano ^f   Moussaoui, Saliha ^g   Laue, Grit ^g   Rassoulpour, Arash ^h   Flik, Gunnar ^h   Huang, Yadong ^a   Muchowski, Joseph M ^a   Masliah, Eliezer ^e   Schwarcz, Robert ^d   Muchowski, Paul J ^a,b,c   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Hellman Family Foundation Program in Alzheimer's Disease Research   (United States)

^d MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF LEICESTER   (United Kingdom)

^g NOVARTIS PHARMA AG   (Switzerland)

^h CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; GLUTAMIC ACID; KYNURENIC ACID; KYNURENINE 3 MONOOXYGENASE; PLATINUM DICHLOROBIS(ISOPROPYLAMINE); RO 618048; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN LEVEL; DRUG ACTIVITY; DRUG PENETRATION; DRUG SYNTHESIS; ENZYME BLOOD LEVEL; ENZYME INHIBITION; FEMALE; HUNTINGTON CHOREA; LIFESPAN; MALE; MOUSE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

MUS MUSCULUS;

EID: 79958021894     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2011.05.020     Document Type: Article

References (54)

1. P. Andiné, A. Lehmann, K. Ellrén, E. Wennberg, I. Kjellmer, T. Nielsen, and H. Hagberg The excitatory amino acid antagonist kynurenic acid administered after hypoxic-ischemia in neonatal rats offers neuroprotection Neurosci. Lett. 90 1988 208 212
2. M.F. Beal, W.R. Matson, E. Storey, P. Milbury, E.A. Ryan, T. Ogawa, and E.D. Bird Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex J. Neurol. Sci. 108 1992 80 87
3. M. Björkqvist, E.J. Wild, J. Thiele, A. Silvestroni, R. Andre, N. Lahiri, E. Raibon, R.V. Lee, C.L. Benn, and D. Soulet A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease J. Exp. Med. 205 2008 1869 1877
4. R.J. Boegman, S.R. el-Defrawy, K. Jhamandas, R.J. Beninger, and S.K. Ludwin Quinolinic acid neurotoxicity in the nucleus basalis antagonized by kynurenic acid Neurobiol. Aging 6 1985 331 336 (Pubitemid 16207687)
5. S. Campesan, E.W. Green, C. Breda, K.V. Sathyasaikumar, P.J. Muchowski, R. Schwarcz, C.P. Kyriacou, and F. Giorgini The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease Curr. Biol. 21 2011 961 966
6. R. Carpenedo, A. Pittaluga, A. Cozzi, S. Attucci, A. Galli, M. Raiteri, and F. Moroni Presynaptic kynurenate-sensitive receptors inhibit glutamate release Eur. J. Neurosci. 13 2001 2141 2147 (Pubitemid 32578800)
7. P. Carrillo-Mora, L.A. Méndez-Cuesta, V. Pérez-De La Cruz, T.I. Fortoul-van Der Goes, and A. Santamaría Protective effect of systemic L-kynurenine and probenecid administration on behavioural and morphological alterations induced by toxic soluble amyloid beta (25-35) in rat hippocampus Behav. Brain Res. 210 2010 240 250
8. C. Cepeda, R.S. Hurst, C.R. Calvert, E. Hernández-Echeagaray, O.K. Nguyen, E. Jocoy, L.J. Christian, M.A. Ariano, and M.S. Levine Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease J. Neurosci. 23 2003 961 969 (Pubitemid 36206187)
9. J. Chin, J.J. Palop, J. Puoliväli, C. Massaro, N. Bien-Ly, H. Gerstein, K. Scearce-Levie, E. Masliah, and L. Mucke Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease J. Neurosci. 25 2005 9694 9703 (Pubitemid 41510910)
10. C.J. Clark, G.M. Mackay, G.A. Smythe, S. Bustamante, T.W. Stone, and R.S. Phillips Prolonged survival of a murine model of cerebral malaria by kynurenine pathway inhibition Infect. Immun. 73 2005 5249 5251 (Pubitemid 41105691)
11. M. DiFiglia, E. Sapp, K.O. Chase, S.W. Davies, G.P. Bates, J.P. Vonsattel, and N. Aronin Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain Science 277 1997 1990 1993 (Pubitemid 27449140)
12. G. Dziewczapolski, C.M. Glogowski, E. Masliah, and S.F. Heinemann Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease J. Neurosci. 29 2009 8805 8815
13. J.A. Eckstein, G.M. Ammerman, J.M. Reveles, and B.L. Ackermann Simultaneous profiling of multiple neurochemical pathways from a single cerebrospinal fluid sample using GC/MS/MS with electron capture detection J. Mass Spectrom. 43 2008 782 790 (Pubitemid 351954812)
14. H. Fillit, W.H. Ding, L. Buee, J. Kalman, L. Altstiel, B. Lawlor, and G. Wolf-Klein Elevated circulating tumor necrosis factor levels in Alzheimer's disease Neurosci. Lett. 129 1991 318 320
15. A.C. Foster, A. Vezzani, E.D. French, and R. Schwarcz Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid Neurosci. Lett. 48 1984 273 278 (Pubitemid 14054435)
16. S. Fukui, R. Schwarcz, S.I. Rapoport, Y. Takada, and Q.R. Smith Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism J. Neurochem. 56 1991 2007 2017
17. F. Giorgini, P. Guidetti, Q. Nguyen, S.C. Bennett, and P.J. Muchowski A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease Nat. Genet. 37 2005 526 531 (Pubitemid 40617282)
18. L. Grégoire, A. Rassoulpour, P. Guidetti, P. Samadi, P.J. Bédard, E. Izzo, R. Schwarcz, and T. Di Paolo Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys Behav. Brain Res. 186 2008 161 167 (Pubitemid 350122751)
19. P. Guidetti, R.E. Luthi-Carter, S.J. Augood, and R. Schwarcz Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease Neurobiol. Dis. 17 2004 455 461 (Pubitemid 39574879)
20. P. Guidetti, G.P. Bates, R.K. Graham, M.R. Hayden, B.R. Leavitt, M.E. MacDonald, E.J. Slow, V.C. Wheeler, B. Woodman, and R. Schwarcz Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice Neurobiol. Dis. 23 2006 190 197 (Pubitemid 43922462)
21. P. Guidetti, L. Amori, M.T. Sapko, E. Okuno, and R. Schwarcz Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain J. Neurochem. 102 2007 103 111 (Pubitemid 46906272)
22. E. Gulaj, K. Pawlak, B. Bien, and D. Pawlak Kynurenine and its metabolites in Alzheimer's disease patients Adv. Med. Sci. 55 2010 204 211
23. J.A. Harris, N. Devidze, B. Halabisky, I. Lo, M.T. Thwin, G.Q. Yu, D.E. Bredesen, E. Masliah, and L. Mucke Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein J. Neurosci. 30 2010 372 381
24. M.P. Heyes, K. Saito, J.S. Crowley, L.E. Davis, M.A. Demitrack, M. Der, L.A. Dilling, J. Elia, M.J. Kruesi, and A. Lackner Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease Brain 115 1992 1249 1273
25. M.P. Heyes, K. Saito, and S.P. Markey Human macrophages convert L-tryptophan into the neurotoxin quinolinic acid Biochem. J. 283 1992 633 635
26. C. Hilmas, E.F. Pereira, M. Alkondon, A. Rassoulpour, R. Schwarcz, and E.X. Albuquerque The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications J. Neurosci. 21 2001 7463 7473 (Pubitemid 32904945)
27. E. Hockly, P.M. Cordery, B. Woodman, A. Mahal, A. van Dellen, C. Blakemore, C.M. Lewis, A.J. Hannan, and G.P. Bates Environmental enrichment slows disease progression in R6/2 Huntington's disease mice Ann. Neurol. 51 2002 235 242 (Pubitemid 34111446)
28. M. Kessler, T. Terramani, G. Lynch, and M. Baudry A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists J. Neurochem. 52 1989 1319 1328 (Pubitemid 19085960)
29. J.C. Liévens, B. Woodman, A. Mahal, O. Spasic-Boscovic, D. Samuel, L. Kerkerian-Le Goff, and G.P. Bates Impaired glutamate uptake in the R6 Huntington's disease transgenic mice Neurobiol. Dis. 8 2001 807 821 (Pubitemid 33055597)
30. L. Mangiarini, K. Sathasivam, M. Seller, B. Cozens, A. Harper, C. Hetherington, M. Lawton, Y. Trottier, H. Lehrach, S.W. Davies, and G.P. Bates Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice Cell 87 1996 493 506 (Pubitemid 26374323)
31. E. Masliah, R.D. Terry, R.M. DeTeresa, and L.A. Hansen Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease Neurosci. Lett. 103 1989 234 239 (Pubitemid 19201259)
32. E. Masliah, M. Alford, R. DeTeresa, M. Mallory, and L. Hansen Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease Ann. Neurol. 40 1996 759 766 (Pubitemid 26415188)
33. B.R. Miller, J.L. Dorner, M. Shou, Y. Sari, S.J. Barton, D.R. Sengelaub, R.T. Kennedy, and G.V. Rebec Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse Neuroscience 153 2008 329 337
34. M. Misztal, J. Skangiel-Kramska, G. Niewiadomska, and W. Danysz Subchronic intraventricular infusion of quinolinic acid produces working memory impairment - a model of progressive excitotoxicity Neuropharmacology 35 1996 449 458 (Pubitemid 26189389)
35. F. Moroni, A. Cozzi, F. Peruginelli, R. Carpenedo, and D.E. Pellegrini-Giampietro Neuroprotective effects of kynurenine-3-hydroxylase inhibitors in models of brain ischemia Adv. Exp. Med. Biol. 467 1999 199 206
36. F. Moroni, A. Cozzi, R. Carpendo, G. Cipriani, O. Veneroni, and E. Izzo Kynurenine 3-mono-oxygenase inhibitors reduce glutamate concentration in the extracellular spaces of the basal ganglia but not in those of the cortex or hippocampus Neuropharmacology 48 2005 788 795 (Pubitemid 40489036)
37. L. Mucke, E. Masliah, G.Q. Yu, M. Mallory, E.M. Rockenstein, G. Tatsuno, K. Hu, D. Kholodenko, K. Johnson-Wood, and L. McConlogue High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation J. Neurosci. 20 2000 4050 4058 (Pubitemid 30365675)
38. K. Nozaki, and M.F. Beal Neuroprotective effects of L-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats J. Cereb. Blood Flow Metab. 12 1992 400 407
39. S. Okuda, N. Nishiyama, H. Saito, and H. Katsuki Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine Proc. Natl. Acad. Sci. USA 93 1996 12553 12558 (Pubitemid 26367182)
40. R. Pellicciari, R.C. Rizzo, G. Costantino, M. Marinozzi, L. Amori, P. Guidetti, H.Q. Wu, and R. Schwarcz Modulators of the kynurenine pathway of tryptophan metabolism: synthesis and preliminary biological evaluation of (S)-4-(ethylsulfonyl)benzoylalanine, a potent and selective kynurenine aminotransferase II (KAT II) inhibitor ChemMedChem 1 2006 528 531 (Pubitemid 43759763)
41. M.N. Perkins, and T.W. Stone An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid Brain Res. 247 1982 184 187 (Pubitemid 12028646)
42. A. Rassoulpour, H.-Q. Wu, S. Ferré, and R. Schwarcz Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum J. Neurochem. 93 2005 762 765 (Pubitemid 40617635)
43. J. Rodgers, T.W. Stone, M.P. Barrett, B. Bradley, and P.G. Kennedy Kynurenine pathway inhibition reduces central nervous system inflammation in a model of human African trypanosomiasis Brain 132 2009 1259 1267
44. L. Romani, T. Zelante, A. De Luca, F. Fallarino, and P. Puccetti IL-17 and therapeutic kynurenines in pathogenic inflammation to fungi J. Immunol. 180 2008 5157 5162
45. S. Röver, A.M. Cesura, P. Huguenin, R. Kettler, and A. Szente Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl) benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase J. Med. Chem. 40 1997 4378 4385 (Pubitemid 28042317)
46. M.T. Sapko, P. Guidetti, P. Yu, D.A. Tagle, R. Pellicciari, and R. Schwarcz Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease Exp. Neurol. 197 2006 31 40 (Pubitemid 41817219)
47. E. Scherzinger, R. Lurz, M. Turmaine, L. Mangiarini, B. Hollenbach, R. Hasenbank, G.P. Bates, S.W. Davies, H. Lehrach, and E.E. Wanker Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo Cell 90 1997 549 558 (Pubitemid 27347244)
48. R. Schwarcz, W.O. Whetsell Jr. R.M. Mangano Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain Science 219 1983 316 318 (Pubitemid 13222319)
49. D. Silva-Adaya, V. Perez-De La Cruz, J. Villeda-Hernandez, P. Carrillo-Mora, I.G. Gonzalez-Herrera, E. Garcia, L. Colin-Barenque, J. Pedraza-Chaverri, and A. Santamaria Protective effect of l-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: Implications of modulating kynurenate as a protective strategy Neurotoxicol. Terat. 33 2010 303 312
50. D.A. Simmons, M. Casale, B. Alcon, N. Pham, N. Narayan, and G. Lynch Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease Glia 55 2007 1074 1084 (Pubitemid 47066747)
51. N. Stoy, G.M. Mackay, C.M. Forrest, J. Christofides, M. Egerton, T.W. Stone, and L.G. Darlington Tryptophan metabolism and oxidative stress in patients with Huntington's disease J. Neurochem. 93 2005 611 623 (Pubitemid 40617621)
52. J.L. Wacker, S.Y. Huang, A.D. Steele, R. Aron, G.P. Lotz, Q. Nguyen, F. Giorgini, E.D. Roberson, S. Lindquist, E. Masliah, and P.J. Muchowski Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease J. Neurosci. 29 2009 9104 9114
53. J. Wang, N. Simonavicius, X. Wu, G. Swaminath, J. Reagan, H. Tian, and L. Ling Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35 J. Biol. Chem. 281 2006 22021 22028 (Pubitemid 44181906)
54. M. Yamamoto, T. Kiyota, M. Horiba, J.L. Buescher, S.M. Walsh, H.E. Gendelman, and T. Ikezu Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice Am. J. Pathol. 170 2007 680 692 (Pubitemid 47339404)